Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership led by the National Institutes of Health (NIH) and coordinated by the Foundation for the National Institutes of Health (FNIH) to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.

ACTIV brings together NIH with its sibling agencies in the Department of Health and Human Services, including the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA); other government agencies, including the Department of Defense (DOD) and Department of Veterans Affairs (VA); the European Medicines Agency (EMA); and representatives from academia, philanthropic organizations and biopharmaceutical companies.

The COVID-19 pandemic is an unprecedented global crisis that has been met with a swift and extraordinary response. The research community is sifting through more than 100 potential preventives and treatments. However, because so many studies are recruiting patients, many of those studies could fail to enroll enough participants to answer their research questions. In addition, lack of coordination could make interpretation and comparison of the results difficult.

With limited resources, there is a need to coordinate and streamline processes to make the best use of biomedical research resources and testing of preclinical compounds. Also, there is a need to prioritize the most promising vaccine candidates and move them into clinical trials in a way that is safe and efficient.

For more information or to view Executive Committee and Working Group members, please visit the NIH website.

Goals:

The goals of ACTIV are to:

  • Develop a collaborative, streamlined forum to identify preclinical treatments
  • Accelerate clinical testing of the most promising vaccines and treatments
  • Improve clinical trial capacity and effectiveness
  • Accelerate the evaluation of vaccine candidates to enable rapid authorization or approval

Media

NIH Press Release (September 23,2020): Fourth large-scale COVID-19 vaccine trial begins in the United States

NIH Press Release (September 10, 2020): NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19

NIH Press Release (August 4, 2020): NIH clinical trial to test antibodies and other experimental therapeutics for mild and moderate COVID-19

NIH Press Release (August 4, 2020): NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients

NIH Press Release (July 27, 2020): Phase 3 clinical trial of investigational vaccine for COVID-19 begins

NEJM (July 1, 2020): Accelerating development of SARS-Cov-2 vaccines: The role for controlled human infection models

JAMA (May 18, 2020): Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An unprecedented partnership for unprecedented times

Science (May 11, 2020): A strategic approach to COVID-19 vaccine R&D

NIH Press Release (April 17, 2020): NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options

Leadership Organizations

Government

Biomedical Advanced Research and Development Authority
Centers for Disease Control and Prevention
Department of Defense
Department of Veterans Affairs
European Medicines Agency
National Institutes of Health
U.S. Food and Drug Administration

Not-for-Profit

Bill & Melinda Gates Foundation
Fred Hutchinson Cancer Research Center
Foundation for the National Institutes of Health
RTI International

Industry

AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Eisai
Eli Lilly and Company
Evotec
Gilead
GlaxoSmithKline
Johnson & Johnson
KSQ Therapeutics
Merck & Co., Inc.
Moderna
Novartis
Novavax
Pfizer
Roche-Genentech
Sanofi
Takeda
Vir Biotechnology

FNIH Contact

Greta Gorman, Director of Communications, ggorman@fnih.org